NZ599957A - Drug combination with theobromine and its use in therapy - Google Patents
Drug combination with theobromine and its use in therapyInfo
- Publication number
- NZ599957A NZ599957A NZ599957A NZ59995710A NZ599957A NZ 599957 A NZ599957 A NZ 599957A NZ 599957 A NZ599957 A NZ 599957A NZ 59995710 A NZ59995710 A NZ 59995710A NZ 599957 A NZ599957 A NZ 599957A
- Authority
- NZ
- New Zealand
- Prior art keywords
- therapy
- theobromine
- opiate
- drug combination
- agent
- Prior art date
Links
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 title abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 229960004559 theobromine Drugs 0.000 title abstract 2
- 239000000890 drug combination Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 abstract 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 abstract 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 abstract 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 2
- 229940127240 opiate Drugs 0.000 abstract 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 abstract 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 abstract 1
- MLQRZXNZHAOCHQ-UHFFFAOYSA-N 3-methylfentanyl Chemical group C=1C=CC=CC=1N(C(=O)CC)C(C(C1)C)CCN1CCC1=CC=CC=C1 MLQRZXNZHAOCHQ-UHFFFAOYSA-N 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 abstract 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 abstract 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 abstract 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 abstract 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 abstract 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 abstract 1
- ZKLXUUYLEHCAMF-UUWFMWQGSA-N Oripavine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ZKLXUUYLEHCAMF-UUWFMWQGSA-N 0.000 abstract 1
- ZKLXUUYLEHCAMF-UHFFFAOYSA-N Oripavine Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(O)C5=C4C23C1O5 ZKLXUUYLEHCAMF-UHFFFAOYSA-N 0.000 abstract 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 abstract 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 abstract 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 abstract 1
- 229960001391 alfentanil Drugs 0.000 abstract 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 abstract 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 1
- 229960001736 buprenorphine Drugs 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical group C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 abstract 1
- 229960004126 codeine Drugs 0.000 abstract 1
- 229960004193 dextropropoxyphene Drugs 0.000 abstract 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 abstract 1
- 229960002069 diamorphine Drugs 0.000 abstract 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 abstract 1
- 229960000920 dihydrocodeine Drugs 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 229960004578 ethylmorphine Drugs 0.000 abstract 1
- 229950004155 etorphine Drugs 0.000 abstract 1
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 abstract 1
- 229960002428 fentanyl Drugs 0.000 abstract 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 abstract 1
- 229960000240 hydrocodone Drugs 0.000 abstract 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 abstract 1
- 229960001410 hydromorphone Drugs 0.000 abstract 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001571 loperamide Drugs 0.000 abstract 1
- 239000007937 lozenge Substances 0.000 abstract 1
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 abstract 1
- 229960004708 noscapine Drugs 0.000 abstract 1
- 229960002085 oxycodone Drugs 0.000 abstract 1
- 229960005118 oxymorphone Drugs 0.000 abstract 1
- 229960005301 pentazocine Drugs 0.000 abstract 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 abstract 1
- 229960000482 pethidine Drugs 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 229960003394 remifentanil Drugs 0.000 abstract 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 abstract 1
- 229960004739 sufentanil Drugs 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 239000006188 syrup Substances 0.000 abstract 1
- 235000020357 syrup Nutrition 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 abstract 1
- 229930003945 thebaine Natural products 0.000 abstract 1
- JWIXXNLOKOAAQT-UHFFFAOYSA-N tipepidine Chemical compound C1N(C)CCCC1=C(C=1SC=CC=1)C1=CC=CS1 JWIXXNLOKOAAQT-UHFFFAOYSA-N 0.000 abstract 1
- 229960000896 tipepidine Drugs 0.000 abstract 1
- 229960004380 tramadol Drugs 0.000 abstract 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 abstract 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 abstract 1
- -1 troche Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0919893.8A GB0919893D0 (en) | 2009-11-13 | 2009-11-13 | Drug composition and its use in therapy |
| PCT/GB2010/051896 WO2011058374A1 (en) | 2009-11-13 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ599957A true NZ599957A (en) | 2014-05-30 |
Family
ID=41509327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ599957A NZ599957A (en) | 2009-11-13 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP2498776A1 (enExample) |
| JP (2) | JP2013510842A (enExample) |
| CN (1) | CN102740853B (enExample) |
| AU (1) | AU2010317668C1 (enExample) |
| BR (1) | BR112012011224A2 (enExample) |
| CA (1) | CA2780704C (enExample) |
| CO (1) | CO6551745A2 (enExample) |
| EC (2) | ECSP12011892A (enExample) |
| GB (1) | GB0919893D0 (enExample) |
| IL (1) | IL219769A0 (enExample) |
| MX (1) | MX2012005538A (enExample) |
| NZ (1) | NZ599957A (enExample) |
| PE (1) | PE20121472A1 (enExample) |
| PH (1) | PH12012500955A1 (enExample) |
| RU (1) | RU2587329C2 (enExample) |
| SG (1) | SG10201407496SA (enExample) |
| UA (1) | UA105940C2 (enExample) |
| WO (1) | WO2011058374A1 (enExample) |
| ZA (1) | ZA201204247B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| GB201111485D0 (en) * | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
| US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| GB0910375D0 (en) | 2009-06-16 | 2009-07-29 | Biocopea Ltd | Drug composition and its use in therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE108064T1 (de) * | 1987-10-08 | 1994-07-15 | Andor Bilas | Stoffgemisch zur stabilisierung der stoffwechsel- lage. |
| CA2170488A1 (en) * | 1993-09-07 | 1995-03-16 | Sekhar Mitra | Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive |
| HUP9700654A2 (hu) | 1997-03-26 | 1999-09-28 | Dezső Korbonits | Teobromin tartalmú köhögéscsillapító készítmények |
| US6608073B1 (en) * | 1998-10-14 | 2003-08-19 | New Millennium Pharmaceutical Research, Inc. | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
| HUP9802716A3 (en) * | 1998-11-25 | 2000-08-28 | Chinoin Gyogyszer Es Vegyeszet | Pharmaceutical composition of analgesic activity |
| ES2528384T3 (es) * | 2001-12-12 | 2015-02-09 | The Government Of The United States Of America, As Represented By The Secretary Department Of Healt | Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación |
| AU2004216550B2 (en) * | 2003-02-28 | 2010-06-03 | Ym Biosciences Inc. | Opioid delivery system |
| CN1593451A (zh) * | 2003-09-12 | 2005-03-16 | 杨喜鸿 | 促进男性勃起的外用药物 |
| JPWO2006064780A1 (ja) * | 2004-12-14 | 2008-06-12 | 塩野義製薬株式会社 | 便秘治療剤 |
| US20080003280A1 (en) * | 2006-06-26 | 2008-01-03 | Levine Brian M | Combination cough treatment compounds and method of treating common coughs |
| KR20080009994A (ko) * | 2006-07-25 | 2008-01-30 | 안국약품 주식회사 | 기침 치료용 조성물 |
-
2009
- 2009-11-13 GB GBGB0919893.8A patent/GB0919893D0/en not_active Ceased
-
2010
- 2010-11-12 SG SG10201407496SA patent/SG10201407496SA/en unknown
- 2010-11-12 WO PCT/GB2010/051896 patent/WO2011058374A1/en not_active Ceased
- 2010-11-12 NZ NZ599957A patent/NZ599957A/en not_active IP Right Cessation
- 2010-11-12 UA UAA201207163A patent/UA105940C2/uk unknown
- 2010-11-12 BR BR112012011224A patent/BR112012011224A2/pt not_active IP Right Cessation
- 2010-11-12 RU RU2012124063/15A patent/RU2587329C2/ru not_active IP Right Cessation
- 2010-11-12 MX MX2012005538A patent/MX2012005538A/es unknown
- 2010-11-12 PE PE2012000650A patent/PE20121472A1/es not_active Application Discontinuation
- 2010-11-12 CN CN201080051628.4A patent/CN102740853B/zh not_active Expired - Fee Related
- 2010-11-12 JP JP2012538416A patent/JP2013510842A/ja active Pending
- 2010-11-12 EP EP10778715A patent/EP2498776A1/en not_active Ceased
- 2010-11-12 PH PH1/2012/500955A patent/PH12012500955A1/en unknown
- 2010-11-12 CA CA2780704A patent/CA2780704C/en not_active Expired - Fee Related
- 2010-11-12 AU AU2010317668A patent/AU2010317668C1/en not_active Ceased
-
2012
- 2012-05-11 EC ECSP12011892 patent/ECSP12011892A/es unknown
- 2012-05-11 CO CO12078022A patent/CO6551745A2/es not_active Application Discontinuation
- 2012-05-11 EC ECSP12011893 patent/ECSP12011893A/es unknown
- 2012-05-13 IL IL219769A patent/IL219769A0/en unknown
- 2012-06-11 ZA ZA2012/04247A patent/ZA201204247B/en unknown
-
2015
- 2015-12-04 JP JP2015237086A patent/JP2016041748A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2780704A1 (en) | 2011-05-19 |
| ZA201204247B (en) | 2013-02-27 |
| EP2498776A1 (en) | 2012-09-19 |
| CA2780704C (en) | 2018-07-17 |
| AU2010317668C1 (en) | 2016-02-11 |
| IL219769A0 (en) | 2012-07-31 |
| RU2012124063A (ru) | 2013-12-20 |
| CN102740853A (zh) | 2012-10-17 |
| PE20121472A1 (es) | 2012-11-30 |
| JP2013510842A (ja) | 2013-03-28 |
| RU2587329C2 (ru) | 2016-06-20 |
| UA105940C2 (uk) | 2014-07-10 |
| GB0919893D0 (en) | 2009-12-30 |
| WO2011058374A1 (en) | 2011-05-19 |
| CN102740853B (zh) | 2015-04-08 |
| SG10201407496SA (en) | 2015-02-27 |
| ECSP12011892A (es) | 2012-09-28 |
| CO6551745A2 (es) | 2012-10-31 |
| AU2010317668A1 (en) | 2012-06-07 |
| JP2016041748A (ja) | 2016-03-31 |
| BR112012011224A2 (pt) | 2017-03-01 |
| AU2010317668B2 (en) | 2015-01-22 |
| ECSP12011893A (es) | 2012-10-30 |
| PH12012500955A1 (en) | 2013-01-07 |
| MX2012005538A (es) | 2012-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ612837A (en) | A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson’s disease | |
| JP2011519930A5 (enExample) | ||
| WO2004045551A3 (en) | Pharmaceutical composition | |
| JP2011126895A5 (enExample) | ||
| JP2010189403A5 (enExample) | ||
| CA2547334A1 (en) | Methods and compositions for deterring abuse of opioid containing dosage forms | |
| NZ599957A (en) | Drug combination with theobromine and its use in therapy | |
| NZ590952A (en) | Use of opioid antagonists for treating urinary retention | |
| HUP0102658A2 (hu) | Opioid agonista és opioid antagonista hatóanyag-kombinációt tartalmazó gyógyszerkészítmény | |
| NZ613079A (en) | Encased tamper resistant controlled release dosage forms | |
| NZ610921A (en) | A tamper resistant dosage form comprising melt extruded particulates in a matrix | |
| JP2006524261A5 (enExample) | ||
| WO2009120889A3 (en) | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists | |
| JP2015521988A5 (enExample) | ||
| JP2011515495A5 (enExample) | ||
| JP2009167214A5 (enExample) | ||
| JP2010511683A5 (enExample) | ||
| RU2007139827A (ru) | Фармацевтические композиции для лечения боли | |
| JP2012519675A5 (enExample) | ||
| EP4253531A3 (en) | Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof | |
| WO2001097780A3 (en) | Pharmaceutical compositions comprising an opioid analgesic | |
| JP2013541567A5 (enExample) | ||
| RU2008152066A (ru) | Сублингвальные таблетки с низкими дозировками опиоидных анальгетиков и способ их получения | |
| AR095160A1 (es) | Formulaciones farmacéuticas a prueba de alteraciones | |
| AR092820A1 (es) | Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2015 BY OLCOTT Effective date: 20141012 |
|
| ASS | Change of ownership |
Owner name: INFIRST HEALTHCARE LIMITED, GB Effective date: 20141106 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2016 BY OLCOTT Effective date: 20151103 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2017 BY 618575 Effective date: 20161102 |
|
| LAPS | Patent lapsed |